RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $59.00. The company’s shares closed yesterday at $41.36.
According to TipRanks, Timashev is a 4-star analyst with an average return of 17.4% and a 40.00% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Edgewise Therapeutics, Biohaven Ltd., and Axsome Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Ltd. with a $60.00 average price target.
BHVN market cap is currently $3.62B and has a P/E ratio of -7.29.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Ltd. (BHVN) Company Description:
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Read More on BHVN:
